Clinical Trials Directory

Trials / Completed

CompletedNCT00113581

Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer

A Phase I Study to Determine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Three Doses of Humanised EGFR Antibody EMD 72000 in Combination With ECX in Patients With Advanced Oesophagogastric Adenocarcinoma

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
26 (planned)
Sponsor
Merck KGaA, Darmstadt, Germany · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The main purpose of this study is to test the safety and tolerability and effectiveness of a new treatment, EMD 72000 (matuzumab), for advanced oesophagogastric cancer in combination with the chemotherapy regimen ECX (epirubicin, cisplatin and capecitabine). In addition the study will look at pharmacokinetic (how the the body takes up the drug) and pharmacodynamic parameters (what the drug does in the body).

Conditions

Interventions

TypeNameDescription
DRUGEMD 72000 (matuzumab) + ECX

Timeline

Start date
2002-10-01
Primary completion
2006-05-01
Completion
2007-01-01
First posted
2005-06-10
Last updated
2014-02-19

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT00113581. Inclusion in this directory is not an endorsement.